AlphAIAlphAI — Financial news for AI agents
theepochtimes.comSEP 152 min read$ABT

Abbott Laboratories to Pay $384 Million Over Infant Formula Contamination Risk Claims

Abbott Laboratories will pay $384 million to settle claims it sold contaminated infant formula through federal and state programs. The DOJ accused Abbott of manufacturing products in unsanitary conditions, which the company denies. The settlement includes payments to the U.S. government, states, and whistleblowers. Abbott recalled its Similac, Alimentum, and EleCare formulas in 2022.

Original reporting
theepochtimes.com
Published Sep 15, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories to Pay $384 Million Over Infant Formula Contamination Risk Claims — source image
Source · theepochtimes.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The $384 M payment represents a material financial hit and may trigger further regulatory scrutiny of Abbott's manufacturing practices.

02

Market read

The settlement is a significant corporate liability event that could depress Abbott's stock and influence sentiment toward the infant‑formula sector.

03

What to watch

Potential for future regulatory actions or additional claims could increase total exposure.

Relevance 8/10Novelty 8/10Timing: announcement today

Background

Abbott faced a whistleblower lawsuit after a 2022 recall of infant formula due to contamination concerns. The DOJ intervened and the settlement resolves the claims.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories agreed to pay about $384 million to settle infant‑formula contamination claims.

Expected impact

Downward pressure on ABT price in the short term as investors reassess risk.

Evidence & confidence

A $384 M settlement is material for a large cap health‑care company and was first disclosed in this article.

Market effects

Sector

May raise scrutiny on other infant‑formula manufacturers and could affect the broader consumer‑health sector.

Regional

U.S. healthcare and consumer staples markets could see modest downside pressure.

Global

Limited to U.S. listed companies; no immediate global ripple.

Counterpoint

What could challenge this read

The settlement amount, while large, may be absorbed by Abbott's cash flow and could be priced in quickly.

Key entities

  • company
    Abbott Laboratories

    U.S. health‑care company producing infant formula.

  • government_agency
    U.S. Department of Justice

    Intervened in the lawsuit and announced the settlement.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 15
$ABTMedAI 8/10

Abbott strikes $385m settlement over major formula recall

Abbott Laboratories agreed to pay $385m to settle US government claims related to its 2022 infant formula recall. The settlement resolves DOJ and state legal cases, with Abbott denying fault. The recall caused a US formula shortage. Abbott will pay $348.7m to the federal government and $36.3m to states. The DOJ accused Abbott of non-compliance and unsafe production practices. Abbott maintains its products were safe, citing negative tests for Cronobacter sakazakii.

just-food.com2 min
SEP 15
$ABTHighAI 9/10

Abbott to pay almost $385 million to settle false claims allegation about infant formula

Abbott Laboratories will pay $384.999 million to settle DOJ allegations of false claims related to its 2022 infant formula crisis. The settlement resolves claims about non-compliance with safety requirements at its Sturgis, MI, and Casa Grande, AZ, facilities. The company's recall led to a nationwide formula shortage. The settlement does not determine liability. Abbott's payment includes $348.7 million to the U.S. and $36.3 million to states. The DOJ alleged Abbott knowingly manufactured contami

foodsafetynews.com2 min
SEP 15
$ABTMedAI 8/10

Abbott to pay US$385 million in US settlement over contaminated infant formula allegations

Abbott Laboratories will pay $385 million to settle US claims over alleged safety violations at its Michigan plant, which produced contaminated infant formula. The settlement follows a 2022 recall linked to infant illnesses and a nationwide formula shortage. The US Justice Department cited unsanitary conditions and inadequate testing. Abbott denies liability. The funds will go to the government, Medicaid, WIC, and whistleblowers.

businesstimes.com.sg2 min